Cubist News (NASDAQ:CBST)

01/20/20155:45PMPRNUSDana Holding Set to Join the S&P MidCap 400
Dana Holding Set to Join the S&P MidCap 400 PR Newswire NEW YORK, Jan. 20, 2015 NEW YORK, Jan. 20, 2015 /PRNewswire/ -- Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc. (NASD: CBST) in the S&P MidCap 400 after the close of trading on Thursday, January 22. S&P 100 & 500 constituent... More...>>
01/13/20158:00AMBWCubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights Agreement dated October 24, 2013 (CVR Agreement) from listing on the NASDAQ Global Select Market on February 2, 2015, contemporaneously with their redemption... More...>>
12/21/20141:51AMBWCubist meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektion...
ZERBAXA geht bestimmte gefährliche und resistente gramnegative Bakterien anErstes in den USA unter dem GAIN-Gesetz zugelassenes Antibiotikum gegen gramnegative Bakterien Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) gab heute bekannt, dass die US-Gesundheitsbehörde FDA sein Antibiotikum ZERBAXA™ (Ceftolozan/Tazobactam... More...>>
12/20/20143:41PMBWCubist annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des i...
ZERBAXA s’attaque à certaines bactéries à Gram négatif graves et résistantes Premier nouvel antibiotique approuvé aux États-Unis dans le cadre de la GAIN Act pour le traitement des bactéries à Gram négatif Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd’hui que la FDA (Food and Drug Administration... More...>>
12/19/20146:08PMBWCubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract & Complicat...
ZERBAXA addresses certain serious and resistant Gram-negative bacteriaFirst new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food and Drug Administration (FDA) approved ZERBAXA™ (ceftolozane/tazobactam) for the treatment... More...>>
12/19/20148:00AMBWMerck Begins Tender Offer to Acquire Cubist
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST). On Dec. 8, 2014, Merck announced its intent to acquire Cubist. Upon the successful closing of the... More...>>
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20171218 16:36:38